A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
NCT ID: NCT07309276
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
864 participants
INTERVENTIONAL
2025-12-30
2028-11-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The plan involves including patients with previously failed standard treatments in advanced NSCLC and ES-SCLC. It consists of two phases: safety introduction and clinical expansion, covering cohorts 1 to 3.
The safety introduction phase will explore the safety of the following combined regimens in the target population:
Queue 1: JS212 + JS207 Queue 2: JS212 + Toripalimab Queue 3: JS212 + JS213
Part Two:
It is planned to include lung cancer patients who have not received any systemic anti-tumor treatment for advanced NSCLC and ES-SCLC in the past. If the SMC decides to further combine chemotherapy, the safety introduction phase should also include to ensure the safety of the subjects.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Queue 1: JS212 + JS207
JS212 will be administered by intravenous infusion on Day 1 of each 21-day cycle.
JS207 will be administered by intravenous infusion on Day 1 of each 21-day cycle.
JS212 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
JS207 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Queue 2: JS212 + Toripalimab
JS212 will be administered by intravenous infusion on Day 1 of each 21-day cycle.
Toripalimab will be administered by intravenous infusion on Day 1 of each 21-day cycle.
JS212 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Toripalimab
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Queue 3: JS212 + JS213
JS212 will be administered by intravenous infusion on Day 1 of each 21-day cycle.
JS213 will be administered by intravenous infusion on Day 1 of each 21-day cycle.
JS212 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
JS213 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JS212 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
JS207 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Toripalimab
Administered by intravenous infusion on Day 1 of each 21-day cycle.
JS213 for Injection
Administered by intravenous infusion on Day 1 of each 21-day cycle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Local advanced, metastatic or recurrent NSCLC.
3. ES-SCLC.
4. According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
6. Expected survival period of ≥ 12 weeks.
7. The functions of important organs meet the requirements.
8. Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study.
9. Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited.
10. The participants voluntarily participate in this study and sign the informed consent.
Exclusion Criteria
1. Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component;
2. NSCLC patients with positive driver mutations;
3. Patients with known meningeal metastasis;
4. Patients with symptomatic brain metastases;
5. Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites;
6. Unatable spinal cord compression;
2\. Participants in Cohort 1 and Cohort 4 need to exclude any of the following conditions:
1. Within one month before the first use of the study drug, any clinically significant hemoptysis or tumor bleeding;
2. High bleeding risk; tumor invading important organs, high risks of perforation, esophageal-tracheal fistula, massive hemoptysis, etc.;
3. Obvious bleeding tendency or severe coagulation dysfunction history, etc;
4. Recent gastrointestinal perforation, gastrointestinal obstruction, trachea-esophageal fistula, abdominal fistula or intra-abdominal abscess, or currently having high-risk factors for hollow organ perforation/ fistula formation, or active inflammatory bowel disease, etc;
5. Presence of severe, non-healed or open wounds, active ulcers or untreated fractures;
6. Have poorly controlled hypertension;
7. Have used antiplatelet drugs or anticoagulant therapy within 14 days;
8. Have experienced a drug-related adverse event that led to permanent discontinuation of the medication during previous Bevacizumab and similar agent treatments;
3\. Have received any of the following treatments:
1. Immune-mediated treatments (only for part Two);
2. Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug;
3. Have been enrolled in another clinical study;
4. Have undergone major surgery within 4 weeks;
5. Have received local small-scale radiotherapy within 14 days;
5.Have known allergies to any study treatment or its excipients or have experienced an allergic reaction.
6.Have experienced a drug-related AE that led to permanent discontinuation of the anti-PD-(L)1 antibody treatment.
7.Have any of the following cardiac examination results:
1. Long QT;
2. Left ventricular ejection fraction (LVEF) \< 50%;
8.Have a history of diagnosed or suspected ILD, drug-induced pneumonia, or other severe lung diseases.
9.Have experienced a severe infection within 4 weeks.
10.Have a history of immunodeficiency, or have a history of organ transplantation and allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation.
11.Have active pulmonary tuberculosis infection.
12.Have active hepatitis.
13\. Uncontrolled concurrent diseases.
14\. Participants who were diagnosed with any other malignant tumor within 5 years.
15\. Female participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
16\. Other conditions for trial participation were not considered appropriate by the investigator.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Caicun Zhou, Ph.D
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS212-002-II-LC
Identifier Type: -
Identifier Source: org_study_id